High Purity Liraglutide Acetate CAS 204656-20-2

Basic Info

Model No.: 204656-20-2

Additional Info

Packaging: AS REQUIRED

Productivity: KGS

Brand: VOLSENCHEM

Transportation: Air

Place of Origin: CHINA

Supply Ability: TRUE MANUFACTURER

Certificate: GMP Peptide

Product Description

On the one hand, Liraglutide improves control of blood glucose. It reduces meal-related hyperglycemia (for 24 hours after administration) by increasing insulin secretion (only) when required by increasing glucose levels, delaying gastric emptying, and suppressing prandial glucagon secretion. On the other hands, Liraglutide has been approved as an injectable adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients. Our Liraglutide CAS NO. 204656-20-2 is high quality and steady. We can provide various of pakaging to meet customers requirement.

Cas No.: 204656-20-2

Synonyms: Liraglutide;Glycine, L-histidyl-L-alanyl-L-alpha-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alpha-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-alpha-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-N6-(N-(1-oxohexadecyl)-L-gamma-glutamyl)-L-lysyl-L-alpha-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl-;Liraglutida;Liraglutida [inn-spanish];Liraglutide [usan:inn];Liraglutidum;Liraglutidum [inn-latin];N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)glp-1-(7-37)-peptide

Molecular Formula: C172H265N43O51

Molecular Weight:

Purity: ≥98%

Packing: Export worthy packing

Material Safety Data Sheet: Available on request

Usage: Liraglutide (CAS 204656-20-2) is one API approved by EU/FDA for the treatment of diabetes,

Liraglutide (CAS 204656-20-2) is a long-acting glucagon-like peptide-1 agonist (GLP-1 agonist). It can be used in the treatment of type 2 diabetes. Liraglutide (CAS 204656-20-2) has been formulated into finished dosage forms and marketed under the trade name of Victoza by Novo Nordisk Pharma.

It has been approved by the European Medicines Agency on July 3, 2009, and by the U.S. Food and Drug Administration (FDA) on January 25, 2010.